Triplet Active in Anti-HER2-Exposed Metastatic Breast Ca

]]>(MedPage Today) -- Dual HER2-directed therapy after prior pertuzumab (Perjeta) exposure was active and well-tolerated when combined with gemcitabine (Gemzar) for women with metastatic HER2-positive breast cancer, a single-arm phase II trial indicated...